ライフサイエンスコーパス: lipopeptide

1 tely 20 times less fluorescent than the free lipopeptide.

2 MBP with the negatively charged, dye-labeled lipopeptide.

3 NRPS cluster that generates a seven-residue lipopeptide.

4 wn for the Pam(3)CysSerLys(4) (Pam(3)CSK(4)) lipopeptide.

5 ramagnetic lipid and a fluorescently labeled lipopeptide.

6 to Francisella lipoproteins and triacylated lipopeptide.

7 to recognize TUL4, FTT1103, and triacylated lipopeptide.

8 ase K digestion, suggesting involvement of a lipopeptide.

9 -6 in combination with a synthetic bacterial lipopeptide.

10 o Gram-positive bacteria, peptidoglycan, and lipopeptide.

11 bserved antibacterial activity of this novel lipopeptide.

12 by Myrcludex B, a synthetic N-acylated preS1 lipopeptide.

13 ular patterns, including di- and triacylated lipopeptides.

14 the binding and insertion process for these lipopeptides.

15 is induced in response to microbial acylated lipopeptides.

16 compared with SVLPs lacking immunomodulatory lipopeptides.

17 eceptor 1/2 (TLR1/2) activation by bacterial lipopeptides.

18 with a mixture of the three CD4-CD8 HSV-1 gD lipopeptides.

19 peptide are involved in CD1c presentation of lipopeptides.

20 base lysine amino group to construct CD4-CD8 lipopeptides.

21 TLR2-TLR1 heterodimers recognize triacylated lipopeptides.

22 e second member of the CD1 family to present lipopeptides.

23 uantity of stereoisomers of bacteria-derived lipopeptides.

24 ymatic cleavage of the liposome-incorporated lipopeptides.

25 ith fatty acids to prepare the corresponding lipopeptides.

26 12, is required for the sensing of bacterial lipopeptides.

27 roduction of six structurally related linear lipopeptides.

28 ll-like receptor (TLR) ligands except diacyl lipopeptides.

29 e peptide component of didehydroxymycobactin lipopeptides.

30 to discriminate between structurally similar lipopeptides.

31 dentified as originating from various cyclic lipopeptides.

32 trometry on the precursor ions of the cyclic lipopeptides.

33 and a TLR2-dependent response to associated lipopeptides.

34 ls to TLR2 ligands, including LPS-associated lipopeptides.

35 volutionary branch of the Pseudomonas cyclic lipopeptides.

36 tivity and selectivity of B. subtilis QST713 lipopeptides.

37 receptor stimulation by pathogen-associated lipopeptides.

38 antibacterial activity of the nisin-derived lipopeptides.

39 tration of palmitate, fibroblast-stimulating lipopeptide-1, a known TLR2 ligand, was a slightly more

40 eoisomer of diacylated macrophage-activating lipopeptide 2 (MALP-2) exclusively activates epithelial

41 TLR2 agonists such as macrophage-activating lipopeptide-2, activity of the M. arthritidis-derived 28

42 with a TLR2/6 ligand, macrophage-activating lipopeptide-2, or a TLR3 ligand, polyinosinic-polycytidy

43 specific TLR2 ligands macrophage activating lipopeptide-2, PAM2-Cys, and Lip19; this was observed to

44 s when stimulated with macrophage-activating lipopeptide-2, polyinosinic-polycytidylic acid, or UVB (

45 2)-dependent manner by macrophage-activating lipopeptide-2.

46 the fact that the effect of cell-penetrating lipopeptide (a pepducin), suggested to act primarily thr

47 Secretion of IL-1beta in response to lipopeptide, a TLR2 agonist, was greatly reduced in ASC-

48 To investigate the newly emerging roles of lipopeptides, accurate measurements of stereoisomers wit

49 Cyclic lipopeptides act against a variety of plant pathogens an

50 idual lipid components in model membranes on lipopeptide activity.

51 imed to investigate the potential of a novel lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost m

52 After incubating CD1a with a mycobacterial lipopeptide Ag, dideoxymycobactin (DDM), we identified a

53 The lipopeptides aggregate in the lipopolysaccharide headgro

54 of TLR1 and TLR2 and a synthetic triacylated lipopeptide agonist.

55 we describe the discovery of a new group of lipopeptide aldehydes, the flavopeptins, and the corresp

56 isolation of the highly N-methylated linear lipopeptides, almiramides A-C (1-3).

57 Pam(3)Cys, a synthetic lipopeptide, also induced SOCS1/SOCS3 expression under t

58 Antimicrobial lipopeptides (AMLPs) are antimicrobial drug candidates t

59 usters responsible for the production of the lipopeptide anabaenolysin.

60 nd to a synthetic tripalmitoylated bacterial lipopeptide analogue (Pam(3)CSK(4)).

61 ibitors, and new lincosamide, oxazolidinone, lipopeptide and cephalosporin derivatives.

62 h between the acyl chains of the synthesized lipopeptide and phospholipid components of the liposomes

63 expected mechanism of action for this unique lipopeptide and suggest future development of this and s

64 s greatly impaired in mediating responses to lipopeptides and a variety of other bacterial agonists f

65 TLR1, revealed that TLR10 senses triacylated lipopeptides and a wide variety of other microbial-deriv

66 th TLR1 and TLR6, is essential for detecting lipopeptides and bacterial cell wall components such as

67 cluding biosurfactants such as antimicrobial lipopeptides and saponins, often show a superior perform

68 T cells induced by these molecularly defined lipopeptides and their protective efficacy were assessed

69 enantiomer of MALP-2 (a diacylated bacterial lipopeptide) and to lipoteichoic acid.

70 covalently linked to a palmitic acid moiety (lipopeptides) and delivered subcutaneously in adjuvant-f

71 mouse models of inflammation: LPS, bacterial lipopeptide, and polymicrobial intra-abdominal sepsis.

72 TLR2 recognizes bacterial lipoproteins/lipopeptides, and lipopolysaccharide activates TLR4.

73 dy, we developed pepducins, cell-penetrating lipopeptide antagonists of CXCR4, to interdict CXCL12-CX

74 f the labeled Trp into the calcium-dependent lipopeptide antibiotic (CDA4a).

75 A54145 is a lipopeptide antibiotic related to daptomycin that permea

76 a sp. CNQ-490 and produced the dichlorinated lipopeptide antibiotic taromycin A in the model expressi

77 Daptomycin is a new lipopeptide antibiotic that is rapidly bactericidal agai

78 Daptomycin is a lipopeptide antibiotic that is used clinically against m

79 Daptomycin is an acidic lipopeptide antibiotic that, in the presence of calcium,

80 Daptomycin is a lipopeptide antibiotic used clinically for the treatment

81 Laspartomycin C is a lipopeptide antibiotic with activity against a range of

82 Daptomycin is a lipopeptide antibiotic with activity against several imp

83 Daptomycin, a lipopeptide antibiotic with activity against virtually a

84 Daptomycin, a novel cyclic lipopeptide antibiotic, exhibits rapid bactericidal acti

85 lated from soil and found to produce a novel lipopeptide antibiotic.

86 (3mGlu) has been found only in three cyclic lipopeptide antibiotics: daptomycin and the A21978C fami

87 and for CD1a demonstrates how a nonribosomal lipopeptide antigen is presented to T cells.

88 ce quenching during loading of a dodecameric lipopeptide antigen, provides a compelling model by whic

89 ediates T cell recognition of glycolipid and lipopeptide antigens that contain either one or two alky

90 cess that includes secretion of surfactin, a lipopeptide antimicrobial agent.

91 The lipopeptide antimicrobial daptomycin has in vitro bacter

92 Daptomycin is a lipopeptide antimicrobial that is rapidly bactericidal a

93 h both the lipid and peptide moieties of the lipopeptide are involved in CD1c presentation of lipopep

94 Antimicrobial peptides and lipopeptides are a promising category of candidates, but

95 Isolated or synthetic lipopeptides are potent vaccine adjuvants, interacting w

96 2 with its lipid A moiety, whereas bacterial lipopeptides are recognized by TLR2.

97 and lipase sensitive, suggesting that small lipopeptides are responsible for the strong IL-8 inducti

98 acterial species revealed that the antigenic lipopeptides are specific for strains of the M. tubercul

99 Collagen-mimetic peptides and lipopeptides are widely used as substrates for matrix de

100 ntracellular pathogen detection and identify lipopeptides as a biochemical class of antigens for T ce

101 ion as criterion when optimizing peptides or lipopeptides as antibiotic leads.

102 2]e(-) reductions to release thioester-bound lipopeptides as corresponding alcohols, using a nonproce

103 egies of introducing ionizable groups on the lipopeptide, as well as the systematic evaluation of che

104 lcium-dependent antibiotics (CDA) are cyclic lipopeptides assembled by nonribosomal peptide synthetas

105 a cocrystallized with a synthetic mycobactin lipopeptide at 2.8 A resolution further reveals that the

106 analogue and a molecular subfamily of cyclic lipopeptides, bananamides 1, 2 and 3.

107 Engineered lipopeptide-based surfaces offer unique presentation opt

108 nd structure-activity analyses of the cyclic lipopeptide battacin which revealed that conjugation of

109 esis that immunization with self-adjuvanting lipopeptide bearing HSV-1 glycoprotein D (gD) T-cell epi

110 x, SSL3 partially covers the entrance to the lipopeptide binding pocket in TLR2, reducing its size by

111 on of the essential TLR2 dimer interface and lipopeptide-binding channel found in TLR1.

112 these metabolites identified a new class of lipopeptide biosurfactants/biofilm modulators (the malle

113 an anti-TLR2 blocking Ab before addition of lipopeptide blocked the phenotypic and functional change

114 Bacterial lipopeptides (bLPs) are increasingly used as adjuvants t

115 of multiple TLR ligands, including bacterial lipopeptides (BLPs), LPS, and the imidazoquinoline compo

116 (TLR 2/1) and diacylated (TLR 2/6) bacterial lipopeptides (BLPs).

117 (4), and Pam(3)C-Lip, a GC-derived synthetic lipopeptide, but not TLR4 agonists including LPS or GC l

118 nding mechanism of a synthetic antimicrobial lipopeptide, C16-KGGK.

119 other class of peptides, cyclic glycosylated lipopeptides called hassallidins, show antifungal activi

120 as seen in the group that was immunized with lipopeptide can be attributed to an influence on the ada

121 ncerted action of magainin 2, the fungicidal lipopeptide class of surfactins from Bacillus subtilis Q

122 Our earlier work on the monoacyl lipopeptide class of TLR2 agonists led to the design of

123 The MBP-lipopeptide complex serves as a protein substrate for se

124 , by interacting with an already formed TLR2-lipopeptide complex, it prevents TLR heterodimerization

125 The removal of TLR2 lipopeptide components from LPS by phenol re-extraction

126 f-assembled nanostructures of various hybrid lipopeptides composed of 1:1 alternating alpha- and E-vi

127 ll cultures with a TLR2 agonist, a synthetic lipopeptide comprising the N-terminal portion of the put

128 ke receptor 2 targeting lipid moiety to form lipopeptide constructs.

129 ke receptor 2-mediated macrophage-activating lipopeptide containing the N-terminal 14 residues of the

130 Vaccination with a mixture self-adjuvanting lipopeptides containing novel HSV-1 immunodominant gD T-

131 was required, as beads coated only with the lipopeptide core failed to delay phagosome-lysosome fusi

132 om Mycobacterium smegmatis are composed of a lipopeptide core unit consisting of a modified C(26)-C(3

133 phobic TLR2 PAMPs within di- and triacylated lipopeptide cores (P2Cys-SVLPs and P3Cys-SVLPs) compared

134 Only SVLPs carrying di- and triacylated lipopeptide cores induced DC activation and maturation i

135 of inflammatory pathways, we tested whether lipopeptides corresponding to the products of the newly

136 e of the appropriate rIFN-beta, to synthetic lipopeptides corresponding to the triacylated N-terminal

137 These preclinical experiments show that this lipopeptide could form the basis of an optimal needle-fr

138 The cyclic antimicrobial lipopeptide daptomycin (DAP) triggers the LiaFSR membran

139 The lipopeptide daptomycin has been approved for use in skin

140 variety of antibiotics including the cyclic lipopeptide daptomycin.

141 However, examination of a wide variety of lipopeptide derivatives indicates that recognition by hu

142 myristoylated preS-peptide (Myrcludex-B), a lipopeptide derived from the pre-S1 domain of the HBV en

143 Lipopeptides derived from lipoproteins activate innate i

144 nded in a TLR2-dependent manner to bacterial lipopeptides derived from Pseudomonas lipoproteins induc

145 ift in the OM topology of sequence-identical lipopeptides due to a single-variable change in environm

146 52 was attributed to thanamycin, a predicted lipopeptide encoded by a nonribosomal peptide synthetase

147 s particles were immunized with a mixture of lipopeptides encompassing the Env.28, Env.362, and Env.3

148 T cell responses to mycobacterial lipid and lipopeptide-enriched Ag preparations were analyzed in im

149 Amphomycin and MX-2401 are cyclic lipopeptides exhibiting bactericidal activities against

150 ntain Bacillus subtilis strains that produce lipopeptide families, such as surfactins (SF), iturins (

151 chemical and genetic analyses identified the lipopeptide fengycin as the major inhibitory molecule pr

152 ramides A and B are immunosuppressant cyclic lipopeptides first reported from the marine alpha-proteo

153 yngbya majuscula strain 19L as a chlorinated lipopeptide for its potent molluscicidal activity.

154 Besides the specificity of this lipopeptide for MAP, the presence of an N-Me-L-valine re

155 flammatory potency of pnLTA, we generated a (lipopeptide-free) Deltalgt mutant of strain D39Deltacps,

156 Bacaucin, a novel cyclic lipopeptide from Bacillus subtilis CAU21, is reported.

157 CD1a presents a family of previously unknown lipopeptides from Mycobacterium tuberculosis, named dide

158 Synthetic analogs of lipopeptides from Treponema pallidum also inhibited Ag p

159 crobial products, including lipoproteins and lipopeptides, from a number of pathogens.

160 nthetic TLR2/6 ligand Fibroblast-stimulating lipopeptide (FSL-1) substantially prolongs survival in b

161 lop unique CXCR4-targeted therapeutics using lipopeptide GPCR modulators called pepducins.

162 To date, pepducins and related lipopeptides have been shown to specifically modulate th

163 ous structure-activity relationships in such lipopeptides have largely been obtained using murine cel

164 air-liquid interface responded to bacterial lipopeptide in a TLR2-dependent manner with induction of

165 inone in clinical use, daptomycin, the first lipopeptide in clinical use, and telithromycin, a ketoli

166 y high (25 microg mL(-1)), the levels of the lipopeptide in roots colonized by B. subtilis are likely

167 a lipophilic drug in aqueous solution and a lipopeptide in serum.

168 B. subtilis QST713 produces the lipopeptides in a ratio of 6 mol SF: 37 mol FE: 57 mol I

169 heterodimers recognize triacylated bacterial lipopeptides, including the synthetic TLR1/2 lipopeptide

170 Stimulation with lipopeptides increased expression of CD83, MHC class II,

171 tail of these three highly immunogenic Th(1) lipopeptides increased survival, lowered the peak of ocu

172 ra from uninfected cattle, reacted with this lipopeptide, indicating potential biological importance.

173 The lipopeptide-induced apoptosis of Schwann cells could be

174 The current studies revealed that lipopeptide-induced TLR2 signaling inhibited induction o

175 lytic domain with a 5S-penem inhibitor and a lipopeptide inhibitor reveal candidate residues that mak

176 > 32-fold decreased susceptibility) to these lipopeptide inhibitors of cell wall synthesis is rare an

177 ment within bacteria cell walls would impair lipopeptide interaction with cell surface TLR2, requirin

178 ed by CD1 and that the peptide moiety of the lipopeptide is recognized by the TCR.

179 Daptomycin, a cyclic lipopeptide, is the only membrane-active antibiotic appr

180 found that biomarkers, identified as cyclic lipopeptides known as fengycin and surfactin, could be d

181 Thus, BPPcysMPEG, a novel diacylated lipopeptide ligand for TLR2-TLR6 heterodimer, induces IL

182 cture of a complex between TLR1, TLR2, and a lipopeptide ligand.

183 peptide epitopes or with Toll-like receptor2 lipopeptide ligands or in three-component vaccines with

184 ide, or mannosyl-phosophomycoketide, but not lipopeptide ligands.

185 previously uncharacterized glycopeptide- and lipopeptide-like antibiotics; thiocoraline-, azinomycin-

186 We report a lipopeptide-like sequence (C10OOc12O) that inflicted out

187 ared with mice immunized with the homologous lipopeptide/lipopeptide (Lipo/Lipo) vaccine, the Lipo/rA

188 The structures of lipopeptides lobocyclamides A (1), B (2), and C (3) were

189 Lipopeptide (LP) biosynthesis was induced in Pseudomonas

190 inflammatory responses induced by bacterial lipopeptide, LPS, and TNFalpha.

191 D32 expression and endocytic activity; these lipopeptide-matured DC also displayed enhanced T cell st

192 The lipopeptides may therefore be useful as potential immuno

193 Such lipopeptides may therefore be useful in fighting gram-ne

194 The echinocandins are large lipopeptide molecules that are inhibitors of beta-(1,3)-

195 The echinocandins are large lipopeptide molecules that, since their discovery approx

196 d microbial agents, including bacterial LPS, lipopeptide, Mycobacterium tuberculosis, cord factor, an

197 mplex with a negatively charged, dye-labeled lipopeptide, (N-heptadecanoyl)-K(dye2)-linker-EEIYGEF-am

198 Motivated by lipoproteins, we report lipopeptide nanoparticles as potent and selective siRNA

199 poration of the peptide into self-assembling lipopeptide nanoparticles that mimic native human high d

200 halassospiramides comprise a large family of lipopeptide natural products produced by Thalassospira a

201 e that the mechanism of T cell activation by lipopeptides occurs via ternary interactions of CD1a/Ag/

202 ructural identification of a major cell wall lipopeptide of MAP, termed Para-LP-01, defined as C20 fa

203 -methylated amino acid within an immunogenic lipopeptide of mycobacteria.

204 Fusions of mRFP1 to short N-terminal lipopeptides of OspA, and surprisingly OppAIV, were targ

205 consisting of multiple ultrashort histidine lipopeptides on a triazacyclophane scaffold, which showe

206 present HIV-derived peptides conjugated to a lipopeptide or HIV-infected cells undergoing apoptosis.

207 wn to inhibit signaling induced by bacterial lipopeptide or lipopolysaccharide (LPS), yet the mechani

208 s to nanogram levels of either the synthetic lipopeptide or OspA lipoprotein agonist.

209 ficient" conditions the TLR2/1 ligand 19 kDa lipopeptide or the TLR4 ligand LPS, monocytes showed inc

210 by acting as mobile carriers of triacylated lipopeptides or lipoproteins.

211 andles for the preparation of glycopeptides, lipopeptides or other peptide conjugates; one such trans

212 Injections of tecemotide (806 mug lipopeptide) or placebo were given every week for 8 week

213 -activity relationship analyses of 17 linear lipopeptide paenipeptin analogues.

214 ysaccharide (LPS) and the synthetic acylated lipopeptide Pam3CSK4.

215 lipopeptides, including the synthetic TLR1/2 lipopeptide Pam3CSK4.

216 e to lipoteichoic acid (LTA) and a synthetic lipopeptide (Pam3CSK4) was investigated.

217 controls, and stimulation with the synthetic lipopeptide Pam3Cys, an agonist of TLR1/2, reduced Treg

218 ted outer surface protein A, and triacylated lipopeptide Pam3CysSerLys4 results in the up-regulation

219 New analogues (UPam) of triacylated lipopeptide Pam3CysSK4, a popular agonist of Toll-like r

220 velopment of first-in-class cell-penetrating lipopeptide "pepducin" antagonists of PAR2.

221 his process is blocked by a cell-penetrating lipopeptide "pepducin," P1pal-7, which is a potent inhib

222 tin but not to beta-sheet defensin HNP-1 and lipopeptide polymyxin B.

223 n 2, the beta-sheet defensins and the cyclic lipopeptide polymyxin B.

224 ly, human TLR2 and -6 exclusively respond to lipopeptides possessing a diacylglycerol group.

225 Our simulations suggest that these lipopeptides prefer to aggregate in solution and alter t

226 Toll-like receptor 1 (TLR2/1) by triacylated lipopeptide, preferentially induced differentiation into

227 panded T cells specifically responded to the lipopeptide preparation.

228 Lipid and lipopeptide preparations as well as complex Ag mixtures,

229 Finally, we showed that bioactive lipopeptides prepared from M. arthritidis grown in serum

230 Surfactin is a cyclic lipopeptide produced by B. subtilis that inhibits the fo

231 Daptomycin, a cyclic lipopeptide produced by Streptomyces roseosporus, is the

232 Anabaenolysins are lipopeptides produced by cyanobacteria with potent lytic

233 rong ermEp* promoter substantially increased lipopeptide production.

234 Lipopeptides promote innate immune response and are rela

235 In contrast, the lipopeptides readily insert into the inner membrane core

236 Synthetic lipopeptides representing the 19-kD and 33-kD lipoprotei

237 Stimulation of epithelial cell cultures with lipopeptide resulted in a small and variable reduction o

238 Injection of radioactively labeled HBVpreS-lipopeptides resulted in rapid accumulation in livers of

239 at lymphocytes treated with this Src-mimetic lipopeptide revealed that this compound is palmitoylated

240 beta mRNA expression induced by LPS, and the lipopeptides S-[2,3-bis(palmitoyloxy)-(2-RS)-propyl]-N-p

241 ity is extraordinarily challenging given the lipopeptide's extreme hydrophobicity and propensity to m

242 TLR2 binding modes reminiscent of bacterial lipopeptide sensing.

243 he lipid tail to generate a library of novel lipopeptides, some of which were as active as daptomycin

244 ted from marine organisms, we identified the lipopeptide somocystinamide A (ScA) as a pluripotent inh

245 tion that is reversed by the presence of the lipopeptide SP-C.

246 The hypothesis that lipopeptide-specific T cells dominate the early BCG-indu

247 , these studies demonstrate the existence of lipopeptide-specific T cells in humans ex vivo.

248 This lipopeptide stimulated the release of the proinflammator

249 ipoarabinomannan- and tripalmitoyl cysteinyl lipopeptide-stimulated cytokine secretion from mononucle

250 low cytometry revealed that this fluorescent lipopeptide substrate represents a highly sensitive mole

251 Nonribosomal lipopeptides such as the plant immunity elicitor surfact

252 odel system, we have demonstrated that these lipopeptides support efficient cell binding and spreadin

253 y S. coelicolor is inhibited by surfactin, a lipopeptide surfactant produced by B. subtilis.

254 In contrast, the fungicidal lipopeptides surfactin, fengycin, and iturin from Bacill

255 eptidase that disrupts interactions with the lipopeptide tail of the antibiotic.

256 -methylated peptide macrocycle attached to a lipopeptide tail, and in the case of the lipoglycopeptid

257 ation, we synthesized analogues with altered lipopeptide tails and identified several with an increas

258 HBVpreS-lipopeptides target to the liver.

259 Surprisingly, natural lipopeptide telomycin precursors were identified when ch

260 The TEM precursor and several semisynthetic lipopeptide TEM derivatives showed rapid bactericidal ki

261 ment of lethal sepsis using cell-penetrating lipopeptides-termed pepducins-that target either individ

262 nificantly enhanced formation of a TLR1.TLR2 lipopeptide ternary complex as measured by size exclusio

263 ced MICs; therefore, 50 mug/ml (standard for lipopeptide testing) is recommended.

264 rprising finding of higher potency in linear lipopeptides than their cyclic counterparts is economica

265 ycin and showed that it is a monochlorinated lipopeptide that belongs to the syringomycin family of a

266 nt with the loss of the ability to produce a lipopeptide that functions as a biosurfactant.

267 Daptomycin is a novel cyclic lipopeptide that is approved by the U.S. Food and Drug A

268 Surfactant protein C (SP-C) is a hydrophobic lipopeptide that is critical for lung function, in part

269 tection of Pam3CSK4, a synthetic triacylated lipopeptide that mimics the structural moieties of its n

270 y antigenic, MHC-II-restricted mycobacterial lipopeptides that are recognized by CD4-positive T lymph

271 Pepducins are cell-penetrating lipopeptides that have enabled chemical and physical acc

272 Three gD lipopeptides, that drive dendritic cell maturation in vi

273 ion by TLR ligands other than LPS, bacterial lipopeptide (TLR2) and CpG (TLR9), via this TLR4-depende

274 eficient DCs failed to present mycobacterial lipopeptide to T cells but had no defects in endocytosis

275 ymphocyte chimeric epitopes (Th-CTL chimeric lipopeptides) to induce herpes simplex virus type 1 (HSV

276 ge of previously unknown telomycin precursor-lipopeptides, to yield 6-methylheptanoic acid and telomy

277 ngth of protective immunity induced by these lipopeptides together with their safety provide a molecu

278 ance NMR measurements determined that cyclic lipopeptide-treated S. aureus exhibited thinning of the

279 TLR2-specific ligands peptidoglycan and the lipopeptide tri-palmitoyl-S-glyceryl-Cys-Ser-(Lys)(4) th

280 to increase the potency of the antimicrobial lipopeptide tridecaptin A1.

281 Toll-like receptor 2-agonistic lipopeptides typified by S-[2,3-bis(palmitoyloxy)-(2RS)-

282 a series of recently developed antimicrobial lipopeptides, using coarse-grained molecular-dynamics si

283 responses induced by the mixture of CD4-CD8 lipopeptide vaccine and the protective efficacy against

284 The lipopeptide vaccine and the rAdv5 vaccine express the im

285 Moreover, we demonstrate that a lipopeptide version of the same peptide is able to bind

286 This novel lipopeptide was membrane lytic and exhibited antibiofilm

287 lved in the synthesis of a virulence-related lipopeptide, was mis-annotated as a fatty acyl-CoA ligas

288 Daptomycin, a new cyclic lipopeptide, was recently approved for the treatment of

289 cifically blocked by L-protein-derived preS1-lipopeptides, we visualized specific HBV receptor/ligand

290 These lipopeptides were isolated from an inactivation mutant o

291 Structures for each of these lipopeptides were proposed based on amino acid analysis

292 idus necator H16 produces a family of linear lipopeptides when grown under low iron conditions.

293 (CD) spectroscopy, we demonstrated that the lipopeptides, when incorporated into liposomes, are demi

294 Daptomycin is a lipopeptide with bactericidal activity that acts on the

295 Variations of this lipopeptide with different fatty acyl moieties (C16 fatt

296 Tridecaptin A1 (TriA1) is a nonribosomal lipopeptide with selective antimicrobial activity agains

297 Novel cyclic lipopeptides with different acyl tails were synthesized

298 crospheres coated with a synthetic Wolbachia lipopeptide (WoLP) of the major nematode Wolbachia TLR2/

299 Deletion of dptGHIJ reduced overall lipopeptide yield and led to production of a series of n

300 tool to guide the isolation of a new cyclic lipopeptide, yuvalamide A, from a marine cyanobacterium.